BRIEF-Mabvax Therapeutics commences patient dosing in MVT-1075 radioimmunotherapy TRIAL
* Mabvax Therapeutics commences patient dosing in MVT-1075 radioimmunotherapy phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers
* Q1 oper. EPS $1.91 vs est $0.77
* Investment income rises 60 pct April 27 RenaissanceRe Holdings Ltd (RNR.N), a Bermuda reinsurer, reported quarterly profit above Wall Street estimates, helped partly by higher investment income.
Net income available to common shareholders for the first quarter was $165 million, or $2.73 a share, compared with a net profit of $97.3 million, or $1.57 a share, in the year-ago period.
Operating income, a measure commonly used by analysts, rose to $116.5 million, or $1.91 a share, compared with $94.2 million, or $1.52 a share, in the year-ago period.
Analysts on average expected the company to earn 77 cents a share, according to Thomson Reuters I/B/E/S.
The company recorded $124.5 million of net negative impact from the Chilean earthquake and Xynthia windstorm in the first quarter.
Net investment income for the quarter was $67.2 million, compared with an investment income of $42.1 million in the year-ago period.
Shares of the company closed at $55.37 Tuesday on the New York Stock Exchange. (Reporting by Supantha Mukherjee in Bangalore; Editing by Aradhana Aravindan)
* Discover Financial Services - Discover cardmembers can now make payments in U.S. Using Samsung Pay on latest Samsung Galaxy smartphones and wearables Source text for Eikon: Further company coverage: